Webinar: A Bond Worth Forming: The Rise of Targeted Covalent Inhibitors
Registration is closed. The webinar recording will be viewable in 48 hours.
Your privacy is important to CAS. More detail about how we use your information is in our privacy policy.
On Demand
Join us for an expert panel on targeted covalent inhibitors.
Before 2000, many drugs that formed a covalent bond with targets did so non-selectively, which often led to undesired side effects when compared to non-covalent drugs. This led to the belief that covalent inhibitors were not ideal drug candidates, resulting in limited development by the pharmaceutical industry. However, covalent drugs have experienced a remarkable resurgence in the last few years as evidenced by the growing number of approvals by the USFDA, including the 2021 approval of Sotorasib to treat lung cancer, which was recently featured on ACS Webinars.
Today, scientists have designed “warheads” with remarkable functionality that exhibit finely tuned reactivity, which only form covalent bonds when positioned at the desired target. Join a panel of experts as they explore the concept of targeted covalent inhibitors, their application in tackling previously unmanageable targets, and gain valuable insights into the covalent inhibitor landscape.
What you will learn
- The theory behind targeted covalent inhibitors and their use against undruggable targets
- An overview of the covalent inhibitor landscape based on data from the CAS Content Collection™
- Trends of the most used warheads, the proteins they target, and indications they address
